Nature Communications (Apr 2021)
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
- Kyle Rosenke,
- Frederick Hansen,
- Benjamin Schwarz,
- Friederike Feldmann,
- Elaine Haddock,
- Rebecca Rosenke,
- Kent Barbian,
- Kimberly Meade-White,
- Atsushi Okumura,
- Shanna Leventhal,
- David W. Hawman,
- Emily Ricotta,
- Catharine M. Bosio,
- Craig Martens,
- Greg Saturday,
- Heinz Feldmann,
- Michael A. Jarvis
Affiliations
- Kyle Rosenke
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Frederick Hansen
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Benjamin Schwarz
- Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Friederike Feldmann
- Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Elaine Haddock
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Rebecca Rosenke
- Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Kent Barbian
- Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Kimberly Meade-White
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Atsushi Okumura
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Shanna Leventhal
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- David W. Hawman
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Emily Ricotta
- Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Catharine M. Bosio
- Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Craig Martens
- Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Greg Saturday
- Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Heinz Feldmann
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Michael A. Jarvis
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- DOI
- https://doi.org/10.1038/s41467-021-22580-8
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 8
Abstract
While vaccines protecting against SARS-CoV-2 infection are approved, currently, there are no drugs suitable for high-risk exposure use against SARS-CoV-2. Here, Rosenke et al. provide evidence that orally delivered MK-4482, a nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model.
